Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CEO Christopher Richard Anzalone Sells 37,967 Shares

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 37,967 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $69.15, for a total value of $2,625,418.05. Following the sale, the chief executive officer now owns 2,116,160 shares of the company’s stock, valued at approximately $146,332,464. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Christopher Richard Anzalone also recently made the following trade(s):

  • On Thursday, October 10th, Christopher Richard Anzalone sold 56,325 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $31.83, for a total value of $1,792,824.75.
  • On Friday, September 20th, Christopher Richard Anzalone sold 4,250 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $29.00, for a total value of $123,250.00.
  • On Tuesday, September 24th, Christopher Richard Anzalone sold 66,645 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $28.20, for a total value of $1,879,389.00.

Arrowhead Pharmaceuticals stock traded down $2.20 during trading hours on Wednesday, hitting $66.46. The stock had a trading volume of 6,593,573 shares, compared to its average volume of 1,774,133. The company has a 50-day moving average of $46.43 and a two-hundred day moving average of $32.86. The company has a market cap of $6.99 billion, a PE ratio of 96.32 and a beta of 1.98. Arrowhead Pharmaceuticals Inc has a fifty-two week low of $10.41 and a fifty-two week high of $73.72.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Monday, November 25th. The biotechnology company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.14 by ($0.03). The firm had revenue of $43.29 million during the quarter, compared to analyst estimates of $36.97 million. Arrowhead Pharmaceuticals had a net margin of 40.27% and a return on equity of 32.30%. On average, equities analysts anticipate that Arrowhead Pharmaceuticals Inc will post -0.29 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the company. Nisa Investment Advisors LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 96.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,020 shares of the biotechnology company’s stock worth $29,000 after buying an additional 500 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth approximately $34,000. Mascoma Wealth Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth approximately $46,000. Pearl River Capital LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth approximately $111,000. Finally, Riverhead Capital Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth approximately $148,000. 68.75% of the stock is owned by institutional investors and hedge funds.

Several analysts recently weighed in on the company. B. Riley restated a “buy” rating and set a $83.00 target price (up previously from $59.00) on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, November 27th. ValuEngine downgraded Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Cantor Fitzgerald restated a “neutral” rating and set a $50.00 target price (up previously from $24.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, November 19th. Chardan Capital restated a “buy” rating and set a $81.00 target price (up previously from $45.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, November 29th. Finally, Robert W. Baird upgraded Arrowhead Pharmaceuticals from a “neutral” rating to an “outperform” rating and increased their target price for the company from $39.00 to $70.00 in a research note on Monday, November 25th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $71.20.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

Further Reading: Different Options Trading Strategies

Insider Buying and Selling by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.